双相障碍药物治疗对自杀、自伤及精神科入院的效果:丹麦全国数据的个体间与个体内研究
该研究基于丹麦1995—2016年33 337例≥15岁双相障碍患者的队列数据,比较锂盐、丙戊酸盐、其他心境稳定剂与抗精神病药在自杀、自伤及精神科入院方面的差异。个体间分析显示锂盐治疗者自杀风险低于未治疗者(HR 0.40,95%CI 0.31—0.51);个体内分析显示锂盐治疗期自伤风险低于非治疗期(HR 0.74,95%CI 0.61—0.91),所有药物类别治疗期精神科入院风险均低于非治疗期(P<0.001)。作者认为锂盐似乎结局更优,但不能排除适应证混杂。
要点
- 锂盐治疗者自杀风险低于未治疗者(HR 0.40,95%CI 0.31—0.51)。
- 个体内分析中锂盐治疗期自伤风险低于非治疗期(HR 0.74,95%CI 0.61—0.91)。
- 所有药物类别治疗期精神科入院风险均低于非治疗期(P<0.001)。
核心结论
- 在所有分析中,锂盐与较低的自杀、自伤及精神科再入院风险相关。
- 就自杀而言,锂盐优于不治疗。
- 尽管不能排除适应证混杂,锂盐在双相障碍治疗中似乎比其他心境稳定剂结局更优。
研究设计与样本
- 采用队列设计,纳入1995—2016年居住在丹麦、年龄≥15岁且诊断为双相障碍的个体。
- 比较锂盐、丙戊酸盐、其他心境稳定剂和抗精神病药的治疗,进行个体间与个体内分析,并校正社会人口学特征和既往自伤。
- 共纳入33 337例双相障碍个体(266 900人年)。
主要发现
- 与未接受治疗者相比,接受锂盐治疗者自杀风险较低(HR 0.40,95%CI 0.31—0.51)。
- 在同一批个体内比较治疗期与非治疗期,锂盐治疗期自伤风险较低(HR 0.74,95%CI 0.61—0.91)。
- 个体内分析中,与未治疗期相比,所有药物类别治疗期精神科入院风险均较低(P<0.001)。
- 个体内分析中锂盐与较低自伤和入院风险的结果得到个体间分析结果的支持。
局限性
- 不能排除适应证混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mood stabilisers are the main treatment for bipolar disorder. However, it is uncertain which drugs have the best outcomes. AIMS: To investigate whether rates of suicide, self-harm and psychiatric hospital admission in individuals with bipolar disorder differ between mood stabilisers. METHOD: A cohort design was applied to people aged ≥15 years who were diagnosed with bipolar disorder and living in Denmark during 1995-2016. Treatment with lithium, valproate, other mood stabilisers and antipsychotics were compared in between- and within-individual analyses, and adjusted for sociodemographic characteristics and previous self-harm. RESULTS: A total of 33 337 individuals with bipolar disorder were included (266 900 person-years). When compared with individuals not receiving treatment, those receiving lithium had a lower rate of suicide (hazard ratio 0.40, 95% CI 0.31-0.51). When comparing treatment and non-treatment periods in the same individuals, lower rates of self-harm were found for lithium (hazard ratio 0.74, 95% CI 0.61-0.91). Lower rates of psychiatric hospital admission were found for all drug categories compared with non-treatment periods in within-individual analyses (P<0.001). The low rates of self-harm and hospital admission for lithium in within-individual analyses were supported by results of between-individual analyses. CONCLUSIONS: Lithium was associated with lower rates of suicide, self-harm and psychiatric hospital readmission in all analyses. With respect to suicide, lithium was superior to no treatment. Although confounding by indication cannot be excluded, lithium seems to have better outcomes in the treatment of bipolar disorder than other mood stabilisers.
引用
- Fitzgerald C, Christensen RHB, Simons J, et al. Effectiveness of medical treatment for bipolar disorder regarding suicide, self-harm and psychiatric hospital admission: between- and within-individual study on Danish national data. Br J Psychiatry. 2022. PMID: 35450547. doi:10.1192/bjp.2022.54
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。